Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SVF for Radiation-Induced Xerostomia
NCT03061110Phase 2Withdrawn
- Sponsor
- City of Hope Chicago
- Start
- Nov 2018
- Primary completion
- Dec 2020
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of autologous adipose stromal vascular fraction in xerostomia, sponsored by City of Hope Chicago. Primary endpoint: Acute Safety Profile (CTCAE) at 72 hours. Planned start Nov 2018; status: withdrawn.
02
Drugs
autologous adipose stromal vascular fraction
03
Conditions
xerostomia
Beyond the preview
Go deeper on NCT03061110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03061110.